Carcinoma, Large Cell: Clinical Trials

20 trials for Carcinoma, Large Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 6 terminated, 1 active not recruiting, 1 no longer available. 7 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 27Terminated 3, Completed 2, Active not recruiting 1, Unknown 1
Phase 15Completed 3, Terminated 1, Withdrawn 1
Phase 35Completed 2, Terminated 2, Recruiting 1
Phase 42Completed 2

Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung
Phase 3RecruitingMaia Biotechnology3002025-12-082026-01-12
THIO Sequenced With Cemiplimab in Advanced NSCLC
6-Thio-2'-Deoxyguanosine, Cemiplimab - Carcinoma, Non-Small-Cell Lung
Phase 2Active not recruitingMaia Biotechnology2272022-06-082026-09-16
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination - Lung Cancer, Small Cell Lung Cancer
CompletedCreative Biosciences (Guangzhou) Co., Ltd.15642022-02-252025-03-21
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer
Phase 3CompletedAriad Pharmaceuticals2752016-05-262021-08-20
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
nab-paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Carcinoma
Phase 4CompletedCelgene1432014-06-092018-09-24
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)
SBRT (stereotactic body radiotherapy), SBPT (stereotactic body proton therapy) - Non-small-cell Lung Cancer
Phase 2TerminatedM.D. Anderson Cancer Center212012-08-012017-12-07
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
Temoporfin - Carcinoma, Non-Small-Cell-Lung
Phase 1WithdrawnUniversity of Arkansas2012-07-012014-01-15
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
PF-02341066/PF-00299804 - Carcinoma, Non-Small Cell Lung, Adenocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)202011-09-012019-12-17
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer
Phase 2CompletedInfinity Pharmaceuticals, Inc.2262011-05-012014-05-19
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
RAD001, Paclitaxel, Carboplatin - Carcinoma, Large Cell, Neuroendocrine Tumors
Phase 4CompletedNovartis Pharmaceuticals492011-04-012016-03-30
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Docetaxel, Oxaliplatin - Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous
Phase 2UnknownKorean South West Oncology Group352011-02-012011-12-22
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
CP 751,871 (Figitumumab), Erlotinib - Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Phase 3TerminatedPfizer5832008-05-012013-07-24
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous
Phase 3TerminatedPfizer6812008-04-012014-01-13
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Temozolomide - Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Phase 2TerminatedMerck Sharp & Dohme LLC532008-03-042017-06-07
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
ZD6474 (vandetanib), Best Supportive Care - Non-Small-Cell Lung Carcinoma
Phase 3CompletedGenzyme, a Sanofi Company11402006-11-012016-09-30
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Motexafin gadolinium and pemetrexed - Non-Small Cell Lung Carcinoma
Phase 2TerminatedPharmacyclics LLC.742006-06-012013-10-31
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Motexafin Gadolinium Injection - Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic
Phase 1CompletedPharmacyclics LLC.362004-11-012009-04-03
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung
Phase 1 / Phase 2CompletedNewLink Genetics Corporation542003-11-012020-05-28
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
EP2101 - Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Phase 1CompletedEpimmune182003-01-012010-03-24
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Brigatinib - Non-small Cell Lung Cancer, Lung Cancer
No longer availableAriad Pharmaceuticals2018-02-06

Narrower conditions

Carcinoma, Non-Small-Cell Lung (19)  ·  Carcinoma, Squamous Cell (18)  ·  Lung Neoplasms (12)  ·  Adenocarcinoma (11)  ·  Carcinoma (6)  ·  Adenocarcinoma of Lung (3)  ·  Carcinoma, Adenosquamous (2)  ·  Bronchitis (1)  ·  Bronchitis, Chronic (1)  ·  Carcinoma, Bronchogenic (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Pneumonia (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Broader conditions

Lung Diseases (20)  ·  Neoplasms by Histologic Type (20)  ·  Neoplasms by Site (20)  ·  Neoplasms, Glandular and Epithelial (20)  ·  Respiratory Tract Diseases (20)  ·  Respiratory Tract Neoplasms (20)  ·  Thoracic Neoplasms (20)  ·  Bronchial Neoplasms (19)  ·  Neoplasms (19)  ·  Carcinoma, Bronchogenic (18)  ·  Neoplasms, Squamous Cell (18)  ·  Carcinoma (14)  ·  Lung Neoplasms (8)  ·  Adenocarcinoma (3)  ·  Disease Attributes (2)

Interventions

Carboplatin (3)  ·  Docetaxel (3)  ·  Paclitaxel (2)  ·  alpha-2'-deoxythioguanosine (2)  ·  brigatinib (2)  ·  cemiplimab (2)  ·  figitumumab (2)  ·  motexafin gadolinium (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Crizotinib (1)  ·  Erlotinib Hydrochloride (1)  ·  Everolimus (1)  ·  Gemcitabine (1)  ·  Oxaliplatin (1)

Sponsors

Ariad Pharmaceuticals (2)  ·  Maia Biotechnology (2)  ·  Pfizer (2)  ·  Pharmacyclics LLC. (2)  ·  Celgene (1)  ·  Creative Biosciences (Guangzhou) Co., Ltd. (1)  ·  Epimmune (1)  ·  Genzyme, a Sanofi Company (1)  ·  Infinity Pharmaceuticals, Inc. (1)  ·  Korean South West Oncology Group (1)  ·  M.D. Anderson Cancer Center (1)  ·  Merck Sharp & Dohme LLC (1)  ·  National Cancer Institute (NCI) (1)  ·  NewLink Genetics Corporation (1)  ·  Novartis Pharmaceuticals (1)

Countries

United States (15)  ·  Taiwan (7)  ·  South Korea (6)  ·  Australia (4)  ·  Canada (4)  ·  France (4)  ·  Germany (4)  ·  Hungary (4)  ·  Italy (4)  ·  Poland (4)  ·  Spain (4)  ·  Austria (3)  ·  Bulgaria (3)  ·  Hong Kong (3)  ·  Romania (3)

Top investigators

Arun Rajan, M.D. (2)  ·  Joe Y. Chang, MD, MS, PHD (1)  ·  Laiyu Liu, PhD (1)  ·  Lei Zheng, PhD (1)  ·  Martin Edelman, MD (1)  ·  Mary E Meek, MD (1)  ·  Sang Byung Bae, M.D. (1)  ·  Teng Jin Ong (1)  ·  Tess Schmalbach, MD (1)  ·  Victor Zaporojan, MD (1)  ·  Victor Zaporojan, Medical Doctor (1)

Results publications

PMID 24888810, PMID 25069747, PMID 25395283, PMID 25881079, PMID 28501139, PMID 28535181, PMID 30280657, PMID 32780660, PMID 38468440, PMID 39707229, PMID 41332393, PMID 41410381, PMID 41740899

NIH funding

2015 (1), 2023 (1), P01CA021239 (1)